Episode 324 - Dr. Anath Shalev - Founder and CSO - TIXiMED

In this episode of the Diabetes Innovators Series, Rob interviews
Dr. Anath Shalev discussing the recent advancements in TIXiMed's
TIX100, an oral therapy for type 1 diabetes. The conversation
covers the successful completion of a phase one study, the
implications of the results, and the potential impact of TIX100 on
diabetes management. Dr. Shalev emphasizes the importance of
addressing beta cell dysfunction and the exciting metabolic signals
observed during the study. The discussion also touches on the
future directions for TIX100 and its role in improving the lives of
diabetes patients. Chapters Chapters 00:00 Introduction to TixiMed
and TIX100 01:16 Phase One Study Results and Implications 05:22
Metabolic Signals and Future Studies 08:11 The Role of TIX100 in
Diabetes Management 09:47 Future Directions and Patient Impact
Resources: TIXiMED Dr. Anath Shalev